Durvalumab with olapirib shows no PFS improvement for platinum-ineligible bladder cancer

Bookmark and Share
Published: 21 Feb 2022
Views: 78
Prof Jonathan Rosenberg - Memorial Sloan Kettering Cancer Center, New York, USA

Prof Jonathan Rosenberg speaks to ecancer in an online interview for ASCO GU 2022 about the BAYOU trial: A phase II, randomised, multicentre, double-blind study of durvalumab in combination with olaparib for first-line treatment of platinum ineligible patients with unresectable, stage IV urothelial carcinoma.

He begins by giving some background to the study, explaining that these patients generally have a poor prognosis and elaborating on the rationale for the trail. He goes on to describe the methods used in the study.

Prof Rosenberg concludes by saying that while this trial did not meet its primary endpoint, there may still be a role for combination therapies using olaparib or other PARP inhibitors in treating urothelial cancer in select patient populations.